XML 26 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED CONDENSED BALANCE SHEETS - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets    
Cash and cash equivalents $ 1,224.6 $ 1,144.0
Short-term investments (Note 5) 473.0 500.5
Accounts receivable, net of allowances of $13.5 and $8.3, respectively 817.6 775.1
Other receivables 59.3 61.8
Inventories (Note 2) 1,207.3 1,168.2
Prepaid expenses 138.1 146.8
Other current assets 250.6 239.3
Total current assets 4,170.5 4,035.7
Long-term investments (Note 5) 455.6 583.9
Property, plant, and equipment, net 1,767.9 1,749.4
Operating lease right-of-use assets 98.4 94.0
Goodwill 1,252.8 1,253.5
Other intangible assets, net 446.8 428.4
Deferred income taxes 776.7 754.6
Other assets (Note 2) 767.6 463.7
Total assets 9,736.3 9,363.2
Current liabilities    
Accounts payable 212.3 201.4
Accrued and other liabilities (Note 2) 873.7 969.1
Operating lease liabilities 24.8 24.9
Total current liabilities 1,110.8 1,195.4
Long-term debt 597.2 597.0
Taxes payable 79.6 80.6
Operating lease liabilities 77.2 73.0
Uncertain tax positions 336.6 339.3
Litigation settlement accrual 82.0 94.2
Other liabilities 266.5 264.3
Total liabilities 2,549.9 2,643.8
Commitments and contingencies (Note 11)
Stockholders' equity    
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding           0.0 0.0
Common stock, $1.00 par value, 1,050.0 shares authorized, 651.8 and 650.5 shares issued, and 602.4 and 601.1 shares outstanding, respectively 651.8 650.5
Additional paid-in capital 2,379.8 2,274.4
Retained earnings 9,344.3 8,992.4
Accumulated other comprehensive loss (Note 12) (233.3) (242.8)
Treasury stock, at cost, 49.4 and 49.4 shares, respectively (5,024.7) (5,024.5)
Total Edwards Lifesciences Corporation stockholders' equity 7,117.9 6,650.0
Noncontrolling interest 68.5 69.4
Total stockholders' equity 7,186.4 6,719.4
Total liabilities and equity $ 9,736.3 $ 9,363.2